Vital Therapies Announces That Topline Results of VTL-308 Fail to Achieve Primary and Secondary Endpoints of Improvement in Survival
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
Cerrado Gold to Host Management Conference Call to Discuss the Purported Unfavourable Opinion of the Environmental Impact Assessment for the Lagoa Salgada Project, Portugal
